
ACHIEVE LIFE SCIENCES, INC.
100
Recent developments highlight Achieve Life Sciences' ongoing efforts to address FDA manufacturing concerns for cytisinicline, corporate governance activities, and preparations for potential FDA approval and product launch.
- Achieve Life Sciences is strengthening the path to FDA approval for cytisinicline, targeting a decision in the first half of fiscal year 2027, following the FDA's Complete Response Letter regarding manufacturing concerns [N7][N8].
- The company held its annual meeting where stockholders considered board slate and share increase proposals [N7].
- Achieve Life Sciences unveiled 52-week safety data for cytisinicline ahead of the FDA decision, supporting its clinical profile [N7].
- The FDA issued a Complete Response Letter to Achieve Life Sciences for cytisinicline NDA over CGMP manufacturing concerns, requiring further manufacturing development [N8].
- Achieve Life Sciences has engaged Omnicom for an innovative U.S. launch strategy to address nicotine dependence with cytisinicline [N7].
Achieve Life Sciences, Inc. operates as a clinical-stage specialty pharmaceutical company developing cytisinicline, a drug candidate aimed at treating nicotine dependence and aiding smoking cessation. The company has submitted a New Drug Application to the FDA and is addressing regulatory feedback related to manufacturing compliance. It has not yet generated revenue from product sales and relies on capital markets and strategic partnerships to fund ongoing research, development, and commercialization efforts. The company maintains a strong liquidity position as of the latest reporting period and has a board with extensive biopharma and investment expertise.
Achieve Life Sciences, Inc. is a clinical-stage specialty pharmaceutical company focused on developing cytisinicline for smoking cessation. The company submitted an NDA in June 2025 and received an FDA Complete Response Letter in June 2026 citing manufacturing concerns. As of September 30, 2026, the company held $201.5 million in cash and marketable securities with strong liquidity ratios. R&D expenses focus on cytisinicline manufacturing and supply chain development. The company has incurred significant accumulated deficits and has not generated product revenue. Financing has been through equity and debt offerings, including a $168 million private placement in April 2026. The company targets an FDA decision in the first half of fiscal 2027 and has engaged Omnicom for U.S. launch strategy. Risks include regulatory uncertainty, manufacturing compliance, and capital needs. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company has advanced cytisinicline through clinical development and regulatory submission, receiving a National Priority Voucher from the FDA, which may facilitate expedited review and commercialization. Its strong liquidity position supports ongoing development and manufacturing scale-up. Engagement with experienced leadership and strategic partners for launch preparation enhances execution capabilities. Successful resolution of manufacturing compliance issues could enable regulatory approval and market entry, addressing a significant unmet need in smoking cessation.
Achieve Life Sciences faces significant risks including regulatory hurdles highlighted by the FDA's Complete Response Letter citing manufacturing concerns, which may delay approval. The company has no current product revenue and depends on capital markets for funding, exposing it to financing risk. Manufacturing scale-up and compliance challenges could increase costs and timelines. Failure to obtain regulatory approval or commercialize cytisinicline would materially impact the company's prospects. The clinical-stage nature and accumulated deficits underscore operational and execution risks.
Achieve Life Sciences' moat is primarily based on its proprietary development of cytisinicline, a novel smoking cessation drug candidate with potential regulatory exclusivity and an FDA National Priority Voucher. The company's progress in clinical development and regulatory engagement, combined with strategic partnerships for manufacturing and commercialization, contribute to its competitive positioning. However, as a clinical-stage company without approved products or revenues, its moat is contingent on successful regulatory approval and market adoption.
• Regulatory Approval Uncertainty: The FDA issued a Complete Response Letter citing CGMP manufacturing concerns, creating uncertainty around the timing and success of cytisinicline approval.
• Manufacturing and Supply Chain Risks: The company is actively addressing manufacturing development and transitioning production to new facilities, which involves operational and compliance risks.
• Capital and Financing Risk: Achieve Life Sciences has incurred significant losses and depends on raising additional capital through equity, debt, or strategic alliances to fund operations and development.
• No Product Revenue: The company has not generated revenue from product sales and may not do so in the near term, increasing reliance on external funding sources.
Business trends: Continued focus on resolving manufacturing compliance issues and advancing cytisinicline regulatory approval; increasing R&D and G&A expenses related to manufacturing and commercialization preparations.
Execution milestones: Targeting FDA decision on cytisinicline in first half of fiscal 2027; progressing manufacturing scale-up and supply chain transitions; engaging strategic partners for U.S. launch.
Key risks: Regulatory approval uncertainty due to manufacturing concerns; dependence on external financing; operational risks in manufacturing scale-up; absence of product revenue.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Achieve Life Sciences, Inc. is a clinical-stage specialty pharmaceutical company focused on developing cytisinicline, a product candidate for smoking cessation.
- The company submitted a New Drug Application (NDA) for cytisinicline to the FDA in June 2025 and received a Complete Response Letter (CRL) from the FDA in June 2026 citing CGMP manufacturing concerns.
- Achieve Life Sciences is actively working on manufacturing development and supply chain activities to address FDA concerns, including transitioning finished drug product manufacturing to a new facility.
- The company has incurred an accumulated deficit of $357.3 million through September 30, 2026 and has not generated any revenue from product sales to date.
- As of September 30, 2026, Achieve Life Sciences had cash, cash equivalents, and marketable securities totaling approximately $201.5 million, with a current ratio of 10.49 and a cash ratio of 10.39, indicating strong liquidity.
- Net cash used in operating activities was $26.1 million for the nine months ended September 30, 2026.
- The company has financed operations through equity offerings, debt financings, and government grants, including a $45 million public offering in June 2025 and a $168 million private placement in April 2026.
- Achieve Life Sciences has convertible debt outstanding with Silicon Valley Bank with principal repayments made in 2026 and $13.1 million principal outstanding as of September 30, 2026.
- Research and development expenses are primarily devoted to cytisinicline, with increased manufacturing and supply chain costs in 2026 related to manufacturing development and inventory purchases.
- General and administrative expenses increased in 2026 due to higher stock-based compensation, employee expenses, and legal costs.
- The company has a board of directors with extensive experience in biopharma, healthcare investment, and life sciences strategy, including a CEO with a medical and investment background.
- Achieve Life Sciences received an FDA National Priority Voucher for cytisinicline in October 2025.
- The company is targeting an FDA decision on cytisinicline in the first half of fiscal year 2027.
- Achieve Life Sciences has engaged Omnicom for an innovative U.S. launch strategy for cytisinicline to address nicotine dependence.
- The company faces risks related to the uncertainty of successful development and regulatory approval of cytisinicline, the need for additional capital, and manufacturing compliance challenges.
- The company has not generated product sales revenue and depends on raising funds through securities offerings, debt, grants, or strategic alliances to finance operations and development.
Generated 2026-11-11
- S1 | 2026-04-30 | 10-K/A
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-11 | www.nasdaq.com | Tech Sell-Off: Two AI Stocks That Are Screaming Buys Right Now | https://www.nasdaq.com/articles/tech-sell-two-ai-stocks-are-screaming-buys-right-now
- N2 | 2026-11-11 | www.nasdaq.com | Einhell Germany 9M Earnings Drop; Revises FY26 Pre-tax Margin View, Backs Revenue Outlook | https://www.nasdaq.com/articles/einhell-germany-9m-earnings-drop-revises-fy26-pre-tax-margin-view-backs-revenue-outlook
- N3 | 2026-11-11 | www.nasdaq.com | Will Netflix Ever Pay a Dividend? | https://www.nasdaq.com/articles/will-netflix-ever-pay-dividend
- N4 | 2026-11-11 | www.nasdaq.com | Bilfinger Q3 Profit Falls, Orders Climb; Confirms FY26, Mid-term Outlook | https://www.nasdaq.com/articles/bilfinger-q3-profit-falls-orders-climb-confirms-fy26-mid-term-outlook
- N5 | 2026-11-11 | www.nasdaq.com | Sionna Posts Wider Loss In Q3 With 46% Workforce Cut; Phase 2 Cystic Fibrosis Trial Set For Q1 2027 | https://www.nasdaq.com/articles/sionna-posts-wider-loss-q3-46-workforce-cut-phase-2-cystic-fibrosis-trial-set-q1-2027
- N6 | 2026-11-11 | www.nasdaq.com | Surgery Partners' Q3 Loss Narrows To $21 Mln; HealthSpan Merger Worth $6 Bln To Close In Q1 '27 | https://www.nasdaq.com/articles/surgery-partners-q3-loss-narrows-21-mln-healthspan-merger-worth-6-bln-close-q1-27
- N7 | 2026-07-10 | www.nasdaq.com | Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting | https://www.nasdaq.com/articles/achieve-life-sciences-stockholders-weigh-board-slate-share-increase-annual-meeting
- N8 | 2026-06-22 | www.nasdaq.com | FDA Issues CRL To Achieve Life Sciences For Cytisinicline NDA Over CGMP Manufacturing Concerns | https://www.nasdaq.com/articles/fda-issues-crl-achieve-life-sciences-cytisinicline-nda-over-cgmp-manufacturing-concerns
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


